^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
vonsetamig (REGN5459)
i
Other names: REGN5459, REGN-5459, REGN 5459
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Regeneron, Sanofi
Drug class:
CD3 agonist, BCMA inhibitor
Related drugs:
over1year
First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM) (clinicaltrials.gov)
P1/2, N=43, Active, not recruiting, Regeneron Pharmaceuticals | Trial completion date: Nov 2023 --> Nov 2025 | Trial primary completion date: Aug 2023 --> Aug 2025
Trial completion date • Trial primary completion date
|
vonsetamig (REGN5459)
over1year
BCMAxCD3 Bispecific Yields Robust Responses in Myeloma. (PubMed, Cancer Discov)
In emerging data from a phase I/II trial, patients with relapsed/refractory multiple myeloma responded well to REGN5459, an investigational BCMA-targeting bispecific T-cell engager. However, despite the drug's low affinity for CD3 on T cells, this design did not mitigate the risk of cytokine release syndrome, a common toxicity.
Journal
|
vonsetamig (REGN5459)
Share via
